What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

T Pallidum Antibody: Test Interpretation Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

T pallidum antibody tests are blood tests that detect the immune response to Treponema pallidum subspecies pallidum, the spirochete bacterium that causes syphilis. They fall into two families: treponemal tests, which detect antibodies directed at T. pallidum antigens and usually stay reactive for life, and nontreponemal tests, which detect antibodies to lipids released during infection and rise and fall with disease activity.

These two families answer different questions. Treponemal tests answer whether a person has ever been infected. Nontreponemal tests answer whether infection is likely active right now and how well it is responding to therapy. Reading one without the other is the single most common source of diagnostic error in syphilis serology, and it is why every modern algorithm pairs them.

What the Tests Actually Measure

Treponemal antibodies

Treponemal tests detect antibodies that bind specific T. pallidum proteins, including recombinant antigens and whole-organism preparations. The immune system produces these antibodies against bacterial components such as the Tp15, Tp17, and Tp47 antigens used in many modern assays. Because these antibodies target the organism itself, they are highly specific for T. pallidum and rarely appear in people who have never been exposed.

The trade-off is persistence. Once a person seroconverts, treponemal antibodies generally remain detectable for life, even after successful treatment. A reactive treponemal test therefore cannot distinguish a cured infection from an active one, and it cannot date the infection. Newer automated assays detect a combination of IgM and IgG antibodies, so they cannot separate recent from remote exposure either [1].

Nontreponemal antibodies (reagin)

Nontreponemal tests detect what is traditionally called reagin. Reagin is not a single antibody against a bacterial protein. It is a mixture of antibodies, largely IgM and IgG, that react with cardiolipin and related lipids. These antibodies appear because infection damages host tissue and releases lipid antigens, and they are measured by flocculation reactions such as the rapid plasma reagin (RPR) test and the Venereal Disease Research Laboratory (VDRL) test.

Reagin has a measurable biologic function. Antibodies purified from VDRL-reactive serum enhance phagocytosis of T. pallidum by macrophages, with 45 percent of macrophages ingesting treponemes in the presence of VDRL antisera versus 14 percent with normal serum [2]. That opsonic activity does not translate into efficient killing, but it confirms that reagin is a genuine immune response rather than an artifact.

Because reagin tracks the host response rather than the organism, it correlates with disease activity. Titers rise during active infection and fall after effective treatment. This is why nontreponemal tests are used for monitoring, and why they are reported as titers (for example 1:8 or 1:32) rather than as simple positive or negative results.

Summary Table: Test Types and What They Mean

Test type	Examples	Target	What a reactive result means	Behavior over time
Treponemal	TP-PA, EIA, CLIA, FTA-ABS, rapid treponemal tests	Antibodies to T. pallidum proteins	Exposure has occurred at some point	Usually reactive for life, treated or not
Nontreponemal	RPR, VDRL, TRUST	Reagin, antibodies to cardiolipin and related lipids	Infection is likely active	Titers rise with activity and fall with cure
IgM-specific	Treponemal IgM, lipoidal IgM assays	IgM only	May suggest early or congenital infection	Not established for routine use
Molecular	T. pallidum PCR, TMA	Bacterial DNA or RNA	Organism is present	Detects organism directly, not antibody

The Two Algorithms in Practice

Traditional algorithm

The traditional algorithm screens with a nontreponemal test such as RPR or VDRL. A reactive screen is then confirmed with a treponemal test such as TP-PA. This sequence was the standard for decades because nontreponemal tests are inexpensive and quantitative, so they double as both screen and activity marker. Its weakness is sensitivity in early primary syphilis. In a study of patients with primary syphilis confirmed by darkfield microscopy, RPR sensitivity was 78 percent and TRUST sensitivity was 55 percent, while TP-PA sensitivity was 95 percent [3]. A nontreponemal screen can therefore miss early infection entirely.

Reverse algorithm

The reverse algorithm screens with an automated treponemal test, typically an enzyme immunoassay (EIA) or chemiluminescence immunoassay (CLIA), then reflexes reactive samples to a nontreponemal test such as RPR. Discordant results (reactive treponemal, nonreactive nontreponemal) are resolved with a second, different treponemal test.

This sequence exists because automated treponemal assays are cheap to run at scale, high-throughput, and objective. In a multi-country comparison of 1,485 men who have sex with men, the ADVIA Centaur CLIA was evaluated against SERODIA-TP-PA, which is often treated as the gold-standard treponemal assay despite being manual and subjectively read [4]. The trade-off of the reverse algorithm is a higher rate of discordant results that require interpretation, because treponemal tests stay reactive for life while nontreponemal tests do not.

The decision path below shows how a single reactive treponemal screen is resolved.

flowchart TD
    A[Patient tested for syphilis] --> B{Screening test type}
    B -->|Nontreponemal first| C[RPR or VDRL titer]
    B -->|Treponemal first| D[EIA or CLIA or TP-PA]
    C --> E{Reactive}
    E -->|Yes| F[Confirm with treponemal test]
    E -->|No| G[Consider early primary syphilis]
    D --> H{Reactive}
    H -->|No| I[Likely not infected]
    H -->|Yes| J[Reflex to RPR or VDRL]
    J --> K{Nontreponemal reactive}
    K -->|Yes| L[Active or recently treated infection]
    K -->|No| M[Second treponemal test]
    M --> N{Second test reactive}
    N -->|Yes| O[Past treated infection or late latent]
    N -->|No| P[Possible false positive]

Interpreting Discordant Results

Reactive treponemal, nonreactive nontreponemal

This pattern is the most common source of confusion. It usually means one of three things: past treated infection, untreated late latent infection, or a false-positive treponemal result. Because treponemal antibodies persist after cure, a person treated years ago will still screen reactive on an EIA or CLIA while their RPR is negative.

Real-world data support this. In an urban county hospital that ran 461 rapid syphilis tests, sensitivity against the reverse algorithm was only 52.2 percent overall, but rose to 83.3 percent after excluding 45 patients with a documented prior history of syphilis. Of the 33 patients who tested negative on the rapid test but positive by EIA, 27 had a documented history of prior treatment [5]. Prior treated infection, not active disease, drove most of the discordance.

The way to separate these possibilities is a second treponemal test using a different format or antigen preparation. If the second test is also reactive, true infection is likely. If it is nonreactive, a false-positive first result becomes more probable.

Nonreactive treponemal, reactive nontreponemal

This pattern is uncommon and usually points to a biologic false-positive reagin result rather than syphilis, because treponemal tests are more sensitive in every stage except possibly very early primary infection. It can also occur in very early primary syphilis before treponemal seroconversion, which is why a negative treponemal test does not fully exclude infection in a patient with a genital ulcer.

Both reactive

When both a treponemal and a nontreponemal test are reactive, active or recently treated infection is the leading interpretation. The nontreponemal titer then becomes the baseline for monitoring. A high titer supports active infection. A low titer with a documented treatment history supports adequate prior therapy.

Stage-by-Stage Antibody Dynamics

A meta-analysis of 167 studies quantified how these antibodies behave across disease stages. Treponemal test positivity was 89.26 percent in primary syphilis, peaked at 97.43 percent in secondary syphilis, and remained high in latent (94.18 percent) and tertiary disease (93.83 percent). Nontreponemal positivity rose from 77.85 percent in primary syphilis to 96.69 percent in secondary syphilis, then fell to 81.92 percent in latent and 71.58 percent in tertiary syphilis [6].

These numbers explain the clinical behavior of the two test families. Treponemal tests stay near ceiling in every stage, which makes them good screens but poor activity markers. Nontreponemal tests swing widely, which makes them good activity markers but unreliable screens in late disease.

The stage-specific gap matters most in primary syphilis. Treponemal tests detected 89 to 96 percent of cases depending on the comparator, while nontreponemal tests detected 55 to 93 percent [3][6]. A patient with a fresh chancre and a nonreactive RPR is not cleared. That patient needs a treponemal test and, when available, direct detection.

False Positives: Causes and Mechanisms

Pregnancy

Pregnancy is a recognized cause of biologic false-positive nontreponemal results. The mechanism involves altered lipid metabolism and placental tissue release, which can generate reagin-like antibodies without treponemal infection. This is one reason all pregnant women are screened with both test families rather than a nontreponemal test alone. A reactive RPR in pregnancy requires treponemal confirmation before it is treated as syphilis.

Autoimmune disease

Autoimmune conditions produce antiphospholipid antibodies that cross-react with the cardiolipin antigen used in RPR and VDRL. A case report described a 16-year-old girl treated for syphilis on the basis of reactive nontreponemal and treponemal tests who was ultimately diagnosed with highly active systemic lupus erythematosus with neuropsychiatric and renal involvement. Her syphilis serology converted to negative after immunosuppressive therapy [7]. Both test families can be affected in autoimmune disease, so a reactive result in a patient with lupus, antiphospholipid syndrome, or another autoimmune condition needs clinical correlation.

Other infections

Epstein-Barr virus is a well-documented cause of false-positive syphilis serology. Three cases of EBV-associated infectious mononucleosis produced concurrent false-positive treponemal and nontreponemal results, with the treponemal reactivity persisting more than 6 months before reverting to negative [8]. That persistence is atypical for true infection, where treponemal tests remain reactive for life, and it is a useful clue.

Heterophile antibodies induced by EBV can interfere directly with assay reagents. A 34-year-old woman had a reactive treponemal antibody result, positive TP-PA, and negative TRUST, but chemiluminescent platforms, immunofluorescence, Western blot, and colloidal gold methods were all nonreactive. After heterophile antibody blocking, the TP-PA and treponemal antibody results returned to negative, confirming a false positive [9]. This case shows that particle agglutination and chemiluminescence assays can both be affected by the same interfering antibody.

Other infections, including other spirochetal diseases, can also produce cross-reactive antibodies. The clinical context (travel history, rash pattern, sexual history) helps separate these from true syphilis.

Direct Detection and the Limits of Serology

Antibody tests have inherent blind spots. They cannot detect infection before seroconversion, they cannot distinguish active from cured infection on the treponemal side, and they can be confounded by interfering antibodies. Molecular methods address some of these gaps by detecting the organism directly.

A study applying ancient-DNA-adapted protocols to serum from ambulatory patients found tpp15 gene amplification in 14 of 17 samples (82.35 percent) and confirmed T. pallidum sequence in 12 of 17 (70.59 percent), demonstrating that molecular detection from serum is feasible even when bacterial loads are low [10]. A transcription-mediated amplification assay for T. pallidum RNA showed 95 percent detection at concentrations between 421 and 5,707 in vitro transcripts, with no cross-reactivity from Treponema denticola, Treponema phagedenis, or Treponema refringens [11].

Molecular testing is not a replacement for serology. It is a complement, most useful when serology is ambiguous, when early infection is suspected, and in congenital syphilis where maternal IgG complicates infant interpretation.

Special Populations

Congenital syphilis

Infants born to mothers with reactive syphilis serology present a specific problem: maternal IgG crosses the placenta, so a reactive treponemal test in a newborn may reflect the mother's antibodies rather than the infant's infection. This is why nontreponemal tests, which better reflect infant disease activity, are often used alone for infant follow-up. A retrospective review found that using nontreponemal tests only in infants would have reduced the number of tests required by at least 50 percent while concentrating resources on the highest-risk infants [12].

IgM testing has been proposed to distinguish infant from maternal antibody, since IgM does not cross the placenta. A study of a research-use-only point-of-care assay measuring treponemal IgM found that mean levels rose with congenital syphilis severity, peaking at 29.9 relative light units in the high-risk group versus 3.5 in controls, but the assay is not yet standard of care [13]. A systematic review of IgM tests in nonpregnant adults concluded that current data are limited by small sample sizes and heterogeneity, and that IgM serologies should not be used routinely outside research settings [14].

Point-of-care testing

Rapid treponemal tests deliver results in minutes rather than days, which matters for same-visit treatment. A combined treponemal and nontreponemal point-of-care test evaluated in Malawi showed 84.8 percent sensitivity and 92.7 percent specificity for the nontreponemal band in mothers compared with RPR, but sensitivity fell to 51.9 percent in infants, rising to 80.0 percent only when RPR titers were higher [15]. Another evaluation of the MedMira Multiplo Complete Syphilis Test found the treponemal component had 90.1 percent sensitivity and 97.9 percent specificity, while the nontreponemal component had 82.5 percent sensitivity overall but 94.1 percent sensitivity for RPR titers of 1:8 or greater [16].

Rapid tests are useful for screening and same-day decisions. They are not a substitute for laboratory-based confirmation and titer monitoring.

Common Mistakes and Limitations

Treating a reactive treponemal test as proof of active infection. Treponemal tests stay reactive for life. A reactive EIA with a negative RPR in a patient with documented prior treatment usually means cured infection, not active disease [5].

Ignoring a negative nontreponemal test in a patient with a genital ulcer. Nontreponemal sensitivity in primary syphilis can be as low as 55 percent depending on the assay and comparator [3]. A negative RPR does not exclude early syphilis.

Assuming a single reactive test is diagnostic. Both test families can produce false positives. Autoimmune disease, pregnancy, EBV infection, and heterophile antibodies are all documented causes [9][7][8].

Failing to run a second treponemal test when results are discordant. The reverse algorithm depends on this step. Without it, a false-positive treponemal screen can lead to unnecessary intervention.

Using IgM tests routinely. The evidence base for IgM serology in nonpregnant adults is weak, with heterogeneous assays and small samples [14].

Forgetting that antibody tests cannot date an infection. Neither family tells you when exposure occurred. A reactive treponemal test in a patient with no symptoms and a negative RPR could represent infection from 20 years ago or from last month.

Relying on serology alone in congenital syphilis. Maternal IgG transfer means infant treponemal results require careful interpretation, and nontreponemal testing is often the better infant marker [12].

Quick Review

Treponemal tests (TP-PA, EIA, CLIA, FTA-ABS) detect antibodies to T. pallidum proteins and usually stay reactive for life.
Nontreponemal tests (RPR, VDRL, TRUST) detect reagin, correlate with disease activity, and are reported as titers.
The traditional algorithm screens with a nontreponemal test and confirms with a treponemal test.
The reverse algorithm screens with an automated treponemal test and reflexes to a nontreponemal test, resolving discordance with a second treponemal test.
Reactive treponemal plus nonreactive nontreponemal usually means past treated infection, late latent infection, or a false positive.
Documented false-positive causes include pregnancy, autoimmune disease, EBV infection, and heterophile antibody interference.
Treponemal positivity stays above 89 percent in every disease stage, while nontreponemal positivity swings from about 56 to 97 percent depending on stage and assay.

Frequently Asked Questions

What does a reactive T pallidum antibody test mean?

A reactive treponemal test means the person has been exposed to T. pallidum at some point. It does not distinguish active from cured infection, so it must be interpreted alongside a nontreponemal test and the clinical history.

Can a treponemal test be positive after successful treatment?

Yes. Treponemal antibodies usually remain detectable for life even after cure. A reactive treponemal test with a negative RPR in a patient with documented prior treatment is an expected finding, not evidence of treatment failure.

What causes a false-positive syphilis test?

Pregnancy, autoimmune diseases such as lupus and antiphospholipid syndrome, Epstein-Barr virus infection, and heterophile antibodies are documented causes. Both treponemal and nontreponemal tests can be affected.

Why do I need two different syphilis tests?

The two test families answer different questions. Treponemal tests establish whether exposure occurred. Nontreponemal tests show whether infection is active and provide a titer for monitoring response. Neither alone gives the full picture.

What does a negative RPR with a positive treponemal test mean?

It usually means past treated infection, untreated late latent infection, or a false-positive treponemal result. A second treponemal test using a different format helps distinguish true infection from a false positive.

Do nontreponemal titers always fall after treatment?

They usually fall, but the decline can be slow, and some patients maintain low stable titers despite adequate therapy. This is sometimes called a serofast reaction, and it is one reason RPR is an imperfect monitoring tool.